ASX:MSBBiotechs
Mesoblast (ASX:MSB) Valuation After Earnings Update And New Ryoncil Revenue Guidance
Why Mesoblast’s latest guidance matters for shareholders
Mesoblast (ASX:MSB) has just paired a detailed half year earnings update with new revenue guidance for its key product Ryoncil, giving investors fresh numbers on both recent performance and management expectations.
The company reported half year revenue of US$51.34 million and a net loss of US$40.16 million, and now forecasts full year 2026 Ryoncil net revenue between US$110 million and US$120 million.
See our latest analysis for...